Boston Scientific makes headway in resolving FDA issues, CEO says

09/22/2008 | Star Tribune (Minneapolis-St. Paul, Minn.)

Boston Scientific is making progress in addressing quality-system problems at three U.S. manufacturing plants and other concerns that were cited in a 2006 warning letter from the FDA, CEO Jim Tobin said at an investors meeting. Resolving these issues will allow the company to launch devices "that drive top-line growth," Tobin said. The company is poised to launch its next-generation drug-coated stent, Taxus Liberte.

View Full Article in:

Star Tribune (Minneapolis-St. Paul, Minn.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director of Product Planning Development; Market Planning, Innovation
Blue Cross Blue Shield of Massachusetts
Quincy , MA
Director, Payer Marketing
Avalere Health
Washington, DC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX